CRSP – crispr therapeutics ag - common shares (US:NASDAQ)

News

Is CRISPR Therapeutics Stock Yesterday's News? [Yahoo! Finance]
How Early Zugo-cel Data and Lilly Partnership Could Impact CRISPR Therapeutics (CRSP) Investors [Yahoo! Finance]
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term [Yahoo! Finance]
CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $80.00 price target on the stock.
CRISPR Therapeutics (NASDAQ:CRSP) had its "market outperform" rating reaffirmed by analysts at Citizens Jmp. They now have a $86.00 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com